The dose of Wegovy will go up every four weeks for the first 17 weeks of treatment
The drug has not been granted approval by Australia's Therapeutic Goods Administration, or any other health authority in the world, for human use and is therefore banned by the World Anti-Doping Agency
Trends in peptide drug discovery
GHK-Cu Contraindications: Patients Who Should Not Use This Peptide GHK-Cu has a strong safety profile at clinical doses
Anyone with metabolic, cardiac, GI, hepatic, or renal disease or who is pregnant, breastfeeding, or planning pregnancy should not consider it without licensed clinical care
In separate-vial workflows, yes they can be administered in the same session, but each compound goes in its own syringe